Add BrightSurf on Google Email

Mayo Clinic


Mayo discovery means individualized ovarian, brain cancer therapies

Researchers developed an algorithm to predict treatment effectiveness in individual patients using a molecular communication pathway. The study found that repurposing ruxolitinib, a drug approved for malignant blood disorders, can overcome resistance to measles virotherapy by increasing its effectiveness by a factor of 1,000.

SourceMayo Clinic·JournalJNCI Journal of the National Cancer Institute·DateMay 16, 2018

New oral anticoagulant drugs associated with lower kidney risks

Researchers found that non-vitamin K antagonist oral anticoagulants are associated with reduced risk of adverse kidney outcomes in patients with atrial fibrillation. The study, published in the Journal of the American College of Cardiology, showed that about 1 in 4 patients taking these medications experienced significant kidney functi...

SourceMayo Clinic·JournalJournal of the American College of Cardiology·DateNov 20, 2017

Physician licensing laws keep doctors from seeking care

A recent study by Mayo Clinic found that nearly 40% of physicians hesitate to seek mental health care due to concerns about their medical license. The researchers discovered that states with licensing requirements asking about past mental health conditions have more reluctant physicians.

SourceMayo Clinic·JournalMayo Clinic Proceedings·DateOct 2, 2017

Mayo Clinic researchers review the clinical potential of senolytic drugs on aging

Senolytic agents target senescent cells, which accumulate with age and contribute to chronic conditions like diabetes, cardiovascular disease, and cancer. Mayo Clinic researchers have identified new screening platforms to find additional senolytic drugs, potentially leading to transformative treatments for aging-related diseases.

SourceMayo Clinic·JournalJournal of the American Geriatrics Society·DateSep 4, 2017

Link between cells associated with aging and bone loss

Researchers discovered a causal link between senescent cells and age-related bone loss in mice. Targeting these cells increased bone mass and strength. The study's findings suggest that senolytic drugs may have widespread application in treating multiple chronic diseases, including osteoporosis.

SourceMayo Clinic·JournalNature Medicine·DateAug 21, 2017

Human gut microbe may lead to treatment for multiple sclerosis

Researchers at Mayo Clinic and University of Iowa found a human gut microbe, Prevotella histicola, that effectively suppresses immune disease in a mouse model of MS. The study suggests that this microbe may play a role in treating MS, an autoimmune disease caused by the immune system's attack on the myelin sheath.

SourceMayo Clinic·JournalCell Reports·DateAug 8, 2017